Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 13/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21701688 | 0.99 | ABCG2 (0.37) | ABCG2ABCB1HTTABCC1HRH4 | |
| SCHEMBL24905526 | 0.99 | ABCG2 (0.37) | ABCG2ABCB1HTTABCC1HRH4 | |
| SCHEMBL24905475 | 0.98 | ABCG2 (0.39) | ABCG2ABCB1HTTABCC1OPRD1 | |
| SCHEMBL24648138 | 0.96 | ABCG2 (0.37) | ABCG2ABCB1HTTABCC1PDK2 | |
| SCHEMBL21701685 | 0.94 | ABCG2 (0.39) | ABCG2ABCB1HTTABCC1PDK2 | |
| SCHEMBL22908161 | 0.93 | ABCG2 (0.38) | ABCG2ABCB1HTTABCC1OPRD1 | |
| SCHEMBL21701689 | 0.93 | MEN1 (0.34) | ABCG2ABCB1HTTABCC1HRH4 | |
| SCHEMBL21151545 | 0.92 | ABCG2 (0.37) | ABCG2ABCB1HTTABCC1OPRD1 | |
| SCHEMBL21701739 | 0.91 | MYC (0.40) | ABCG2ABCB1PDK2ADORA2AADORA1 | |
| SCHEMBL24647583 | 0.91 | ABCG2 (0.44) | ABCG2ABCB1ABCC1PDK2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220376178-A1 | ORGANIC LIGHT-EMITTING DEVICE | LG CHEM, LTD. (KR) | 2022-11-24 | — | — | US | disclosed |
| US-20200048230-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT INCLUDING SAME | LG CHEM, LTD. (KR) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048230-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT INCLUDING SAME | CRY1, CRY2, CYP1A1 | ABCG2 2349/4885ABCB1 1101/4885HTT 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.